Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1478 • ACR Convergence 2023
Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review
Alain Sanchez-Rodriguez¹, Mariana Gonzalez-Treviño¹, Hannah Langenfeld², Cynthia Crowson³, Maria Valenzuela-Almada⁴, Alejandro Rabinstein⁵, Larry J. Prokop⁶, Isabel Valenzuela-Almada⁷ and Ali Duarte-Garcia³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Department of Pediatrics, Children’s National Medical Center, Washington, DC, ⁵Department of Neurology, Mayo Clinic, Rochester, MN, ⁶Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ⁷Division of Internal Medicine, Hospital Medica Sur, Mexico City, Mexico
Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with SLE and Posterior reversible encephalopathy syndrome (PRES). Methods: We performed a multicenter cohort…
Abstract Number: 1496 • ACR Convergence 2023
Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis
Kenneth Kalunian¹, Robert Levin², Sreejith Parameswaran³, nelson kopyt⁴, Stephen Connelly⁵, Eugene Sun⁵, Katie Kim⁵, maple fung⁵ and Manish Rathi⁶, ¹University of California San Diego, La Jolla, CA, ²South Florida University, Tampa, FL, ³JIPMER, New Delhi, India, ⁴LeHigh University, LeHigh, PA, ⁵Equillium, La Jolla, CA, ⁶Postgraduate Institute of Medical education and Research, Chandigarh, India
Background/Purpose: Itolizumab is a first-in-class, non-depleting, monoclonal antibody against the co-stimulatory receptor CD6 that blocks its interaction with ALCAM, to inhibit Teff cell activity and…
Abstract Number: 1580 • ACR Convergence 2023
CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon
Calvin Law¹, Vanessa Wacleche², Ye Cao³, Arundhati Pillai¹, Alice Horisberger⁴, Sabrina Bracero³, Viktoriya Skidanova³, Zhihan Li³, Ifeoluwakiisi Adejoorin², Isaac Benque³, Diana Pena Nunez³, Daimon Simmons², Joshua Keegan⁴, Lin Chen³, John Sowerby³, Accelerating Medicines Partnership (AMP): RA/SLE², Elena Massarotti², Karen Costenbader⁴, Michael Brenner⁴, James Lederer⁴, Judd Hultquist¹, Jaehyuk Choi¹ and Deepak Rao², ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Expansion of B cell-helper T cells including T follicular helper (Tfh) and T peripheral helper (Tph) cells is a prominent feature of systemic lupus…
Abstract Number: 1652 • ACR Convergence 2023
Lupus Research Action Network: Increasing Minority Clinical Trial Participation Through Peer Leaders
Melicent Miller¹, Stephanie Slan¹, Rosalind Ramsey-Goldman², Rodlescia Sneed³, Candace Feldman⁴, Patrick Wildman¹, Tori Justin⁵, Lydia Oberholtzer⁵ and Joy Buie⁶, ¹Lupus Foundation of America, Washington, DC, ²Northwestern University, Chicago, IL, ³Wayne State University, Detroit, MI, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Sharp Insight, LLC, Montgomery County, MD, ⁶Lupus Foundation of America, York, SC
Background/Purpose: Black/African American people with lupus (PWL) experience greater disease prevalence and severity than White PWL. The need for more racial and ethnic diversity amongst…
Abstract Number: 1859 • ACR Convergence 2023
Examining Hydroxychloroquine Prescribing and SLE Damage in a Statewide Lupus Cohort
Jenna Cormier¹, Bryn Sutherland¹, Yiran Jiang², David Gazeley³, Jonathan Katz⁴, Shalvi Parikh⁴, Carlos Torres⁵, Eden Charles⁵, Ang Yu⁶, Felix Elwert⁶ and Christie M. Bartels⁷, ¹Medical College of Wisconsin, Milwaukee, WI, ²Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, ³Medical College of Wisconsin, Wauwatosa, WI, ⁴Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Department of Sociology, University of Wisconsin, Madison, WI, ⁷University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease that disproportionately affects women, racially and ethnically minoritized populations, and people of lower socioeconomic status (SES).…
Abstract Number: 2261 • ACR Convergence 2023
Burden of Flare and Organ Damage in Systemic Lupus Erythematosus (SLE) in the Asia Pacific Region: A Multicenter Cohort Study
Rangi Kandane-Rathnayake¹, Dominique Milea², Worawit Louthrenoo³, Alberta Hoi⁴, Vera Golder¹, Jiacai Cho⁵, Aisha Lateef⁵, Shue-Fen Luo⁶, Yeong-Jian J Wu⁷, Laniyati Hamijoyo⁸, Sargunan Sockalingam⁹, Zhanguo Li¹⁰, Sandra Navarra¹¹, Leonid Zamora¹¹, Masayoshi Harigai¹², Yasuhiro Katsumata¹², Madelynn Chan¹³, Yanjie Hao¹⁴, Zhuoli Zhang¹⁵, Sean O’Neill¹⁶, Fiona Goldblatt¹⁷, Shereen Oon¹⁸, Xiaomeng Xu², Aldo Amador Navarro Rojas¹⁹, Sang-Cheol Bae²⁰, Chak Sing Lau²¹, Mandana Nikpour²² and Eric Morand²³, ¹Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ²GlaxoSmithKline, Value Evidence and Outcomes, Singapore, Singapore, ³Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁴Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ⁵National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, ⁶Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁷Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ⁸Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁹University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹⁰Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, ¹¹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹²Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁴St Vincent’s Hospital Melbourne, Department of Rheumatology, Melbourne, Australia, ¹⁵Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁶Department of Medicine, University of New South Wales, Kensington, Australia, ¹⁷Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ¹⁸University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ¹⁹GlaxoSmithKline, Medical Affairs, Singapore, Singapore, ²⁰Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ²¹University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ²²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ²³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia
Background/Purpose: Up to 50% of patients with SLE develop irreversible organ damage within 10 years of diagnosis, and most experience recurrent disease flares of varying…
Abstract Number: 2277 • ACR Convergence 2023
Patients with Systemic Lupus Erythematosus: A Comparative Study Between Two Large, Multi-centric, Spanish and Argentinian Registers, Focused on Outcomes Differences
Iñigo Rúa-Figueroa¹, Rosana M Quintana², JULIA MARTINEZ BARRIO³, Mercedes García⁴, Maria Galindo-Izquierdo⁵, Lucila Garcia⁶, Jaime Calvo- Alén⁷, Carla Gobbi⁸, Esther Uriarte Isacelaya⁹, Paula Alba⁸, Eva Tomero Muriel¹⁰, Verónica Bellomio¹¹, Mercedes Freire González¹², Susana Roverano⁶, Victor Martinez-Taboada¹³, Analia Patricia Alvarez¹⁴, Eva Salgado-Pérez¹⁵, Cesar Enrique Graf¹⁶, Paloma Vela¹⁷, Cecilia Pisoni¹⁴, Antonio Fernandez-Nebro¹⁸, Valeria Arturi¹⁹, Clara Sanguesa Gomez²⁰, Catalina Gomez¹⁴, Javier Narvaez²¹, Zulema Plaza²², Gregorio Santos Soler²³, Silvia Papasidero²⁴, José Ángel Hernández Beriain²⁵, Raul Paniego⁶, Angela Pecondón²⁶, Maria Celina De La Vega⁶, Oihane Ibarguengoitia-Barrena²⁷, Emma Civit⁸, Gema Bonilla²⁸, Luciana Gonzalez Lucero¹⁴, Vicente Torrente-Segarra²⁹, Maria Victoria Martire⁶, Ana Paula Cacheda³⁰, Rodrigo Aguila Maldonado¹⁴, Maria J. García-Villanueva³¹, Sergio Gordon¹⁴, Clara Moriano Morales³², Marina Micelli⁶, Loreto Horcada³³, Romina Nieto³⁴, Nuria Lozano Rivas³⁵, Gretel Rausch¹⁴, Guillermo Pons-Estel³⁴ and Jose-Maria Pego-Reigosa³⁶, ¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Centro Regional de Enfermedades Autoinmunes y Reumticas (CREAR), Grupo Oroño, Rosario, Argentina, ³Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁴Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ⁵Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁶RELESSAR, CABA, Argentina, ⁷Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁸RELESSAR, Cordoba, Argentina, ⁹Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ¹⁰Rheumatology, Hospital La Princesa, Madrid, Spain, ¹¹RELESSAR, Tucuman, Argentina, ¹²Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹³Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ¹⁴Study Group of the Argentine Society of Rheumatology for Systemic Lupus Erythematosus, Buenos Aires, Argentina, ¹⁵Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, ¹⁶RELESSAR, ENTRE RIOS, Argentina, ¹⁷Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, ¹⁸Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁹RELESSAR, La Plata, Argentina, ²⁰Severo Ochoa Hospital, Madrid, Spain, ²¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²²Universidad Autónoma de Madrid, Madrid, Spain, ²³Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, ²⁴Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²⁵Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁶Hospital Universitario Miguel Servet, Zaragoza, Madrid, Spain, ²⁷Galdakao-Usansolo University Hospital, Bilbao, Spain, ²⁸Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁹Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ³⁰Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, ³¹Hospital Ramón y Cajal, Madrid, Spain, ³²Rheumatology, Hospital Universitario de León, León, Spain, ³³Hospital de Navarra, Pamplona, Spain, ³⁴RELESSAR, Rosario, Argentina, ³⁵Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ³⁶Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multi-organ involvement, associated with substantial morbidity and mortality. A characteristic that distinguishes lupus patients…
Abstract Number: 2295 • ACR Convergence 2023
Predictors of Adherence to Cervical Cancer Screening Guidelines Among Patients with Systemic Lupus Erythematosus
Lindsay Cho and Alexandra Legge, Dalhousie University, Halifax, NS, Canada
Background/Purpose: Women with systemic lupus erythematous (SLE) are at increased risk for cervical dysplasia and cervical cancer. In our jurisdiction, current guidelines recommend that average-risk…
Abstract Number: 2311 • ACR Convergence 2023
Effect on Lupus Outcomes of the Protective Allele at rs1876453 in the Complement Receptor 2 Gene
Ani Oganesyan¹, Rachel Sharp², Philip O’Neill³, Cynthia Aranow⁴, Laurent Arnaud⁵, Anca Askanase⁶, Sang-Cheol Bae⁷, Sasha Bernatsky⁸, Ian Bruce⁹, Jill Buyon¹⁰, Winn Chatham¹¹, Ann Clarke¹², Nathalie Costedoat-Chalumeau¹³, Mary Anne Dooley¹⁴, Paul R. Fortin¹⁵, Ellen Ginzler¹⁶, Dafna Gladman¹⁷, Caroline Gordon¹⁸, John G. Hanly¹⁹, Murat Inanç²⁰, David Isenberg²¹, Soren Jacobsen²², Andreas Jonsen²³, Kenneth Kalunian²⁴, Diane L. Kamen²⁵, S. Sam Lim²⁶, Anselm Mak²⁷, Eric Morand²⁸, Christine Peschken²⁹, Michelle Petri³⁰, Bernando A. Pons-Estel³¹, Anisur Rahman³², Rosalind Ramsey-Goldman³³, John Reynolds³⁴, Juanita Romero-Diaz³⁵, Guillermo Ruiz-Irastorza³⁶, Jorge Sanchez-Guerrero³⁷, Kristjan Steinsson³⁸, Murray Urowitz³⁹, Ronald van Vollenhoven⁴⁰, Evelyne Vinet⁴¹, Alexandre Voskuyl⁴², Daniel Wallace⁴³, Susan Manzi⁴⁴, Kenneth L. Jones⁴⁵ and Susan A. Boackle⁴⁶, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Feinstein Institutes for Medical Research, Manhasset, NY, ⁵University Hospitals of Strasbourg, Strasbourg, France, ⁶Columbia University Medical Center, New York, NY, ⁷Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁹University of Manchester, Manchester, United Kingdom, ¹⁰NYU Grossman School of Medicine, New York, NY, ¹¹University of Alabama at Birmingham, Birmingham, AL, ¹²University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ¹³Inserm DR Paris 5, Paris, France, ¹⁴Raleigh Neurology Associates, Chapel Hill, NC, ¹⁵Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁶SUNY Downstate Health Sciences University, Brooklyn, NY, ¹⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁸Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹⁹Dalhousie University, Halifax, NS, Canada, ²⁰Istanbul University, Istanbul, Turkey, ²¹University College London, London, United Kingdom, ²²Rigshospitalet, Copenhagen, Denmark, ²³Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²⁴University of California San Diego, La Jolla, CA, ²⁵Medical University of South Carolina, Charleston, SC, ²⁶Emory University, Atlanta, GA, ²⁷Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²⁸Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ²⁹University of Manitoba, Winnipeg, MB, Canada, ³⁰Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ³¹Study Group of the Argentine Society of Rheumatology for Systemic Lupus Erythematosus, Buenos Aires, Argentina, ³²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³³Northwestern University, Chicago, IL, ³⁴University of Birmingham, Birmingham, United Kingdom, ³⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ³⁶Hospital Universitario Cruces, Barakaldo, Spain, ³⁷University Health Network, Toronto, ON, Canada, ³⁸Landspitali University Hospital, Reykjavik, Iceland, ³⁹Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴⁰Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴¹McGill University Health Centre, Montréal, QC, Canada, ⁴²Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴⁴Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁴⁵Bioinformatics Solutions, Sheridan, WY, ⁴⁶None, Denver, CO
Background/Purpose: Systemic lupus erythematosus is a heterogenous autoimmune disease characterized by inflammatory damage to multiple organ systems. We have shown that the single-nucleotide polymorphism (SNP)…
Abstract Number: 2327 • ACR Convergence 2023
Hydroxychloroquine Improves Low Complement Levels
Michelle Petri¹, Rebecca Jacobson², Andrea Fava³ and Larry Magder⁴, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: Low complement is associated with clinical disease activity and future organ damage in patients with systemic lupus erythematosus (SLE). Prior studies from Japan, although…
Abstract Number: 2347 • ACR Convergence 2023
Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus by Race and Ethnicity: A Large Post Hoc Integrated Analysis of Five Clinical Trials
Saira Sheikh¹, Amit Saxena², Angela Carroll³, Christine Henning³, Julia HN Harris⁴, Bernard Rubin⁵, David D'Cruz⁶ and Alvin F Wells⁷, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²New York University Grossman School of Medicine, Rheumatology, New York, NY, ³GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ⁶Guy’s Hospital, Louise Coote Lupus Unit, London, United Kingdom, ⁷Advocate Health Department of Rheumatology, Franklin, WI
Background/Purpose: Belimumab (BEL) is approved for the treatment of active SLE, and lupus nephritis, with standard therapy.1 The prevalence and severity of SLE tend to…
Abstract Number: 2460 • ACR Convergence 2023
Health Care Segregation, but Not Metropolitan Area Segregation, Magnifies Racial Disparities in Hospital Outcomes of Pediatric Lupus
Joyce Chang¹, Jessica Liu¹, Laura Berbert¹, Edie Weller¹, Gabrielle Alonzi¹, Emily Smitherman², Pooja Patel³, Mary Beth Son⁴ and Karen Costenbader⁵, ¹Boston Children's Hospital, Boston, MA, ²University of Alabama at Birmingham, Birmingham, AL, ³Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Racial disparities and hospital-level variation in pediatric SLE (pSLE) outcomes are well described, but it is not known how the racial and ethnic composition…
Abstract Number: 2553 • ACR Convergence 2023
Prevalence, Determinants and Outcomes of Target Attainment in SLE Patients with Clinically Active Disease in a Large Multinational Prospective Lupus Cohort
Yanjie Hao¹, Dylan Hansen², Rangi Kandane-Rathnayake³, Worawit Louthrenoo⁴, Yi-Hsing Chen⁵, Jiacai Cho⁶, Aisha Lateef⁶, Laniyati Hamijoyo⁷, Shue-Fen Luo⁸, Yeong-Jian J Wu⁹, Sandra Navarra¹⁰, Leonid Zamora¹⁰, Zhanguo Li¹¹, Sargunan Sockalingam¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Zhuoli Zhang¹⁴, Madelynn Chan¹⁵, Jun Kikuchi¹⁶, Tsutomu Takeuchi¹⁷, Sang-Cheol Bae¹⁸, Fiona Goldblatt¹⁹, Sean O’Neill²⁰, Kristine Ng²¹, Annie Law²², BMDB Basnayake²³, Nicola Tugnet²⁴, Sunil Kumar²⁵, Cherica Tee²⁶, Michael Tee²⁶, Yoshiya Tanaka²⁷, Chak Sing Lau²⁸, Vera Golder³, Alberta Hoi²⁹, Eric Morand³⁰, Shereen Oon³¹ and Mandana Nikpour³², ¹The University of Melbourne Department of Medicine at St Vincents Hospital Melbourne, Melbourne, Australia, ²Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, ³Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁴Chiang Mai University Hospital, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, ⁷Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁸Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁹Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ¹⁰University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹¹Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, ¹²University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹³Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹⁴Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁵Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁶Keio University School of Medicine, Tokyo, Japan, ¹⁷Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ¹⁸Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ¹⁹Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ²⁰Department of Medicine, University of New South Wales, Kensington, Australia, ²¹Waitemata DHB, Auckland, New Zealand, ²²Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²³Division of Nephrology, Teaching Hospital Kandy, Adelaide, Australia, ²⁴Auckland District Health Board, Auckland, New Zealand, ²⁵Middlemore Hospital, Auckland, New Zealand, ²⁶University of the Philippines, Manila, Philippines, ²⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁸University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ²⁹Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ³⁰Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³¹University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ³²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: There is increasing interest in adopting the principle of treating to target (T2T) in systemic lupus erythematosus (SLE). Remission and low disease activity states…
Abstract Number: 0120 • ACR Convergence 2023
Incidence and Prevalence of Systemic Lupus Erythematosus in Urban China, 2013-2017: A Nationwide Population-based Study
Mucong Li¹, Chaiquan Li², Mengzhuo Cao³, Ke Lu², Chanyuan Wu³, Jiuliang zhao¹, Qian Wang⁴, Xinping Tian¹, Xun Tang², Mengtao Li¹, xiaofeng Zeng⁴ and Pei Gao², ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking University, Beijing, China, ³Peking Union Medical College Hospital, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Systemic lupus erythematosus (SLE) is becoming a public health concern because of increasing disease and economic burdens. Epidemiological information on SLE, especially its incidence…
Abstract Number: 0184 • ACR Convergence 2023
Material Need Insecurities Are Associated with Worse Patient-Reported Outcomes Among Individuals with SLE
Donavon Sandoval-Heglund¹, Eric Roberts², Joonsuk Park², Maria Dall'Era², Kamil Barbour³, Cristina Lanata⁴, Kurt Greenlund³, Caroline Gordon⁵, Patti Katz⁶ and Jinoos Yazdany², ¹University of California San Francisco School of Medicine, La Quinta, CA, ²University of California San Francisco, San Francisco, CA, ³Centers for Disease Control and Prevention, Atlanta, GA, ⁴National Human Genome Research Institute, Washington, DC, ⁵Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶University of California San Francisco, San Rafael, CA
Background/Purpose: Lower socioeconomic status is associated with greater disease activity and mortality in systemic lupus erythematosus (SLE); however, mechanisms driving this are yet to be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].